Unveiling Pancreatic Cancer's Sweet Defense: A New Immunotherapy Target
Pancreatic cancer's resistance to immunotherapy has long puzzled researchers, but a recent study from Northwestern University offers a fascinating insight into this mystery. In a groundbreaking paper published in Cancer Research, Mohamed Abdel-Mohsen, PhD, and his team reveal how pancreatic tumor cells employ a clever sugar-based strategy to evade the immune system's attack. This discovery not only sheds light on a novel immune-evasion mechanism but also presents a promising new therapeutic approach.
"It took our team six years to uncover this mechanism," Abdel-Mohsen shared. "Pancreatic cancer disguises itself in sugar, essentially tricking the immune system into thinking it's a normal cell. It's like a wolf in sheep's clothing."
The Sugar Shield: A Barrier to Immune Attack
Pancreatic ductal adenocarcinoma (PDAC), the most common and aggressive form of pancreatic cancer, remains one of the most challenging cancers to treat. One of the key hurdles is its "immunosuppressive microenvironment," which prevents immune cells from recognizing and eliminating tumor cells. Abdel-Mohsen's research focuses on a crucial aspect of this puzzle: the role of sialic acid sugars in PDAC cells.
These sialic acid sugars are attached to a cell surface protein called integrin α3β1, which acts as a decoy. They bind to a receptor on immune cells called Siglec-10, creating a "glyco-immune checkpoint." This interaction triggers inhibitory signals in myeloid cells, particularly tumor-associated macrophages (TAMs), causing them to stand down and not attack the cancer cells.
"When Siglec-10 binds to sialic acid, it sends a 'stand down' signal to the immune cells," Abdel-Mohsen explained. "It tells them there's nothing to see here, so the macrophages don't engulf the cancer cells, allowing the tumor to grow."
A Novel Immune Checkpoint for Pancreatic Cancer
Previous studies had identified similar sugar-based mechanisms in breast and ovarian cancers, involving Siglec-10 and a different ligand called CD24. However, PDAC cells typically lack CD24. Abdel-Mohsen's team used advanced techniques like flow cytometry, mass spectrometry, and live imaging to discover that PDAC cells utilize integrin α3β1 as a novel Siglec-10 binding partner.
This finding highlights a broader principle: different cancers may employ distinct sugar-coated disguises to exploit the same immune checkpoint pathway. "We were surprised to find that the same immune receptor, Siglec-10, is being hijacked by a completely different ligand in pancreatic cancer," Abdel-Mohsen noted. "It demonstrates cancer's adaptability in deceiving our immune system."
Reactivating the Immune System
To counter this sugar-based deception, Abdel-Mohsen's team developed an antibody that blocks Siglec-10 on myeloid cells, preventing it from binding to the sialic-acid-coated integrin on tumor cells. This blockade reactivates the macrophages, allowing them to directly attack tumor cells through phagocytosis and "teach" T cells how to recognize and destroy the cancer.
"Myeloid cells are the teachers of the immune system," Abdel-Mohsen explained. "If they're silenced, T cells can't learn how to attack the tumor. But when we block Siglec-10, we reactivate those teachers."
In laboratory experiments, treatment with the Siglec-10 antibody alone significantly reduced pancreatic tumor growth in mice by 36-40%. The next step, according to Abdel-Mohsen, is to combine this antibody with existing immunotherapies that target T cells, such as PD-1 or PD-L1 inhibitors, to activate both arms of the immune response simultaneously.
"Current immunotherapies mostly focus on T cells," he said. "But if the teachers are asleep, the T cells can't learn. Our approach wakes up the teachers, while other drugs activate the students. Together, they can mount a stronger attack."
Beyond Pancreatic Cancer
While this study focused on pancreatic cancer, Abdel-Mohsen believes the mechanism may extend to other "cold" tumors that resist immunotherapy, such as glioblastoma. "Many cancers use this same trick," he said. "They cover themselves with sialic acid, though often on different proteins. Even virally infected cells use similar sugar disguises to fool the immune system."
This observation emphasizes the importance of glycobiology, a field that studies the complex sugars decorating cell surfaces, and its underappreciated role in immune regulation. "Glycobiology and glyco-immunology are still not mainstream," Abdel-Mohsen noted. "But we're seeing that these sugar interactions are critical in how the immune system decides what to attack or ignore. Ignoring them has limited our understanding of immune evasion."
Moving Towards Clinical Trials
Abdel-Mohsen and his team are now collaborating with clinicians at Northwestern's Lurie Cancer Center to advance their findings toward clinical trials. "We're completing preclinical studies to ensure the antibody is both safe and effective," he said. "Ultimately, our goal is to combine this with chemotherapy or existing immunotherapies for a more comprehensive treatment strategy."
Abdel-Mohsen emphasized that pancreatic cancer won't be defeated by a single therapy. "There's no one-size-fits-all solution," he said. "It will be an arsenal of solutions working together to outsmart the tumor."
The implications of this research extend far beyond pancreatic cancer. Targeting sugar-based immune checkpoints like Siglec-10 could open up new therapeutic avenues for diseases that currently have limited effective treatments. "By targeting glycans, we're unlocking a new layer of immune regulation," Abdel-Mohsen said. "This could be the key to bringing immunotherapy success to pancreatic cancer and potentially other stubborn cancers as well."
